BCHE and Alzheimer disease: Based on their FRAP values, the tested amodiaquine derivatives can be considered as highly promising anti-AD drugs in terms of multitarget drugs targeting cholinesterase as their main activity and attenuating adverse effects of oxidative stress associated with AD as an additional beneficial activity.